IGI Laboratories Announces the Submission of Two More ANDAs
IGI Laboratories, Inc. (NYSE: IG) today announced that it has submitted two additional abbreviated new drug applications (ANDAs) to the US FDA, bringing the company's total number of submissions to eight.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.